Edwards Lifesciences Corporation
EW
$81.83
$0.670.83%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.14% | 8.23% | 8.57% | 4.48% | 0.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.14% | 8.23% | 8.57% | 4.48% | 0.81% |
| Cost of Revenue | 12.89% | 10.32% | 14.22% | 9.24% | 7.81% |
| Gross Profit | 8.18% | 7.71% | 7.20% | 3.34% | -0.85% |
| SG&A Expenses | 12.38% | 12.18% | 13.11% | 8.69% | 6.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 76.88% | 47.57% | -- | -187.27% | -200.00% |
| Total Operating Expenses | 14.59% | 10.77% | 12.38% | -0.83% | -2.81% |
| Operating Income | -2.78% | 2.15% | -0.45% | 18.47% | 9.73% |
| Income Before Tax | 7.75% | 15.38% | 12.80% | 4.14% | 1.74% |
| Income Tax Expenses | 43.96% | 14.80% | -0.20% | -21.26% | -19.55% |
| Earnings from Continuing Operations | 3.66% | 15.45% | 14.43% | 7.69% | 4.87% |
| Earnings from Discontinued Operations | 2,331.11% | 1,539.00% | 1,446.10% | 1,840.48% | 19.68% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 66.67% | 43.59% | 63.33% | 35.71% | 125.00% |
| Net Income | 181.58% | 195.71% | 197.68% | 190.65% | 6.01% |
| EBIT | -2.78% | 2.15% | -0.45% | 18.47% | 9.73% |
| EBITDA | -2.54% | 2.27% | 0.22% | 17.12% | 9.47% |
| EPS Basic | 185.96% | 200.24% | 202.32% | 195.52% | 7.39% |
| Normalized Basic EPS | 1.85% | 6.57% | 4.58% | 21.99% | 12.89% |
| EPS Diluted | 186.40% | 200.96% | 203.88% | 196.91% | 7.69% |
| Normalized Diluted EPS | 2.08% | 6.78% | 4.75% | 22.25% | 13.16% |
| Average Basic Shares Outstanding | -2.28% | -1.85% | -1.48% | -1.16% | -1.27% |
| Average Diluted Shares Outstanding | -2.50% | -2.06% | -1.67% | -1.37% | -1.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |